| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3505 | 2019 |
| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature medicine 23 (6), 703-713, 2017 | 3239 | 2017 |
| OncoKB: a precision oncology knowledge base D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ... JCO precision oncology 1, 1-16, 2017 | 2368 | 2017 |
| Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab AM Menzies, DB Johnson, S Ramanujam, VG Atkinson, ANM Wong, ... Annals of Oncology 28 (2), 368-376, 2017 | 858 | 2017 |
| Overall survival benefit with tebentafusp in metastatic uveal melanoma P Nathan, JC Hassel, P Rutkowski, JF Baurain, MO Butler, M Schlaak, ... New England Journal of Medicine 385 (13), 1196-1206, 2021 | 704 | 2021 |
| Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis SP D’Angelo, J Larkin, JA Sosman, C Lebbé, B Brady, B Neyns, ... Journal of clinical oncology 35 (2), 226-235, 2017 | 624 | 2017 |
| Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ... Cell 185 (3), 563-575. e11, 2022 | 439 | 2022 |
| Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies AP Algazi, KK Tsai, AN Shoushtari, RR Munhoz, Z Eroglu, JM Piulats, ... Cancer 122 (21), 3344-3353, 2016 | 391 | 2016 |
| Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma MH Pollack, A Betof, H Dearden, K Rapazzo, I Valentine, AS Brohl, ... Annals of Oncology 29 (1), 250-255, 2018 | 367 | 2018 |
| Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma AR Moore, E Ceraudo, JJ Sher, Y Guan, AN Shoushtari, MT Chang, ... Nature genetics 48 (6), 675-680, 2016 | 344 | 2016 |
| Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors C Valero, M Lee, D Hoen, K Weiss, DW Kelly, PS Adusumilli, PK Paik, ... Nature communications 12 (1), 729, 2021 | 329 | 2021 |
| Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment SP D’Angelo, AN Shoushtari, NP Agaram, D Kuk, LX Qin, RD Carvajal, ... Human pathology 46 (3), 357-365, 2015 | 329 | 2015 |
| The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma AN Shoushtari, RR Munhoz, D Kuk, PA Ott, DB Johnson, KK Tsai, ... Cancer 122 (21), 3354-3362, 2016 | 303 | 2016 |
| Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicenter, randomized trial (SUMIT) RD Carvajal, S Piperno-Neumann, E Kapiteijn, PB Chapman, S Frank, ... Journal of Clinical Oncology 36 (12), 1232-1239, 2018 | 278 | 2018 |
| Neoadjuvant relatlimab and nivolumab in resectable melanoma RN Amaria, M Postow, EM Burton, MT Tetzlaff, MI Ross, C Torres-Cabala, ... Nature 611 (7934), 155-160, 2022 | 242 | 2022 |
| Vascular endothelial growth factor-C and CC chemokine receptor 7 in tumor cell–lymphatic cross-talk promote invasive phenotype A Issa, TX Le, AN Shoushtari, JD Shields, MA Swartz Cancer research 69 (1), 349-357, 2009 | 233 | 2009 |
| Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium RN Amaria, AM Menzies, EM Burton, RA Scolyer, MT Tetzlaff, ... The Lancet Oncology 20 (7), e378-e389, 2019 | 226 | 2019 |
| Metastasis and immune evasion from extracellular cGAMP hydrolysis J Li, MA Duran, N Dhanota, WK Chatila, SE Bettigole, J Kwon, RK Sriram, ... Cancer discovery 11 (5), 1212-1227, 2021 | 225 | 2021 |
| The association between tumor mutational burden and prognosis is dependent on treatment context C Valero, M Lee, D Hoen, J Wang, Z Nadeem, N Patel, MA Postow, ... Nature genetics 53 (1), 11-15, 2021 | 215 | 2021 |
| Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma MR Middleton, C McAlpine, VK Woodcock, P Corrie, JR Infante, ... Clinical Cancer Research 26 (22), 5869-5878, 2020 | 204 | 2020 |
